Skip to main content

Genome BC Receives $800K from Canadian Government

NEW YORK (GenomeWeb News) – The Canadian government’s Western Economic Diversification division is making a four-year, CAN$800,000 ($805,000) investment in the province of British Columbia’s Genome BC. The funding is intended to support multi-stakeholder, Western Canadian genomics networks.
 
With the new funding, Genome BC expects to create its own set of genomics networks — encompassing industry, provincial governments, universities, federal laboratories, and other research agencies — and to participate in other Western Canadian genomics networks led by Genome Prairie and Genome Alberta.
 
These networks, which are expected to have implications for everything from human health to natural resources and the environment, are intended to promote collaboration, decrease research duplication, and help the genomics community secure investments from other partners.
 
“For the first time, genome organizations across the West will have a platform to collaborate with western companies and research organizations on market-driven research and the commercialization of new technologies,” Russ Hiebert, a Member of Parliament for South Surrey, BC, said in a statement.
 
Canada has six genomics and proteomics networks funded through the central organization Genome Canada.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.